- Home
- XFOR vs ACRS Comparison
XFOR vs ACRS Comparison
Compare XFOR & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- ACRS
- Stock Information
- Founded
- XFOR 2014
- ACRS 2012
- Country
- XFOR United States
- ACRS United States
- Employees
- XFOR N/A
- ACRS N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- XFOR Health Care
- ACRS Health Care
- Exchange
- XFOR Nasdaq
- ACRS Nasdaq
- Market Cap
- XFOR 84.3M
- ACRS 165.7M
- IPO Year
- XFOR N/A
- ACRS 2015
- Fundamental
- Price
- XFOR $3.15
- ACRS $1.84
- Analyst Decision
- XFOR Strong Buy
- ACRS Strong Buy
- Analyst Count
- XFOR 3
- ACRS 9
- Target Price
- XFOR $34.17
- ACRS $9.25
- AVG Volume (30 Days)
- XFOR 1.5M
- ACRS 815.1K
- Earning Date
- XFOR 11-12-2025
- ACRS 11-05-2025
- Dividend Yield
- XFOR N/A
- ACRS N/A
- EPS Growth
- XFOR N/A
- ACRS N/A
- EPS
- XFOR N/A
- ACRS N/A
- Revenue
- XFOR $32,774,000.00
- ACRS $16,789,000.00
- Revenue This Year
- XFOR $1,313.84
- ACRS N/A
- Revenue Next Year
- XFOR N/A
- ACRS N/A
- P/E Ratio
- XFOR N/A
- ACRS N/A
- Revenue Growth
- XFOR 5721.31
- ACRS N/A
- 52 Week Low
- XFOR $1.35
- ACRS $1.05
- 52 Week High
- XFOR $26.83
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- XFOR 50.35
- ACRS 47.21
- Support Level
- XFOR $2.88
- ACRS $1.83
- Resistance Level
- XFOR $3.23
- ACRS $2.16
- Average True Range (ATR)
- XFOR 0.36
- ACRS 0.11
- MACD
- XFOR -0.11
- ACRS -0.03
- Stochastic Oscillator
- XFOR 18.36
- ACRS 10.00
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.